Vimarsana
Biggest News Aggregation in the World

Peter Droc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Peter Droc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Peter Droc Today - Breaking & Trending Today

Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated C - Vimarsana News

Lonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated C

Lonza Group AG / Key word(s): ExpansionLonza Announces New Filling Line for Commercial Supply of Antibody-Drug Conjugates for a Dedicated Customer 13.10.2023 / 08:00 CET/CEST The new cGMP filling line at Lonza’s Stein (CH) site will enable handling and filling of bioconjugates for commercial supply Expansion of fill...

Lonza drug product manufacturing line in Visp is operational - Vimarsana News

Lonza drug product manufacturing line in Visp is operational

Swiss CDMO Lonza has increased capacity and capabilities at its Visp, Switzerland site, with the completion of a new line for cGMP clinical and commercial drug product manufacturing.

Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH) - Vimarsana News

Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp (CH)

Lonza Group AG / Key word: Expansion Lonza Completes Clinical and Commercial Drug Product Manufacturing Line in Visp 29.03.2023 / 09:00 CET/CEST Lonza increases capacity and... | March 29, 2023

Licensing Agreement to Drive Multi-specific Biotherapeutics Development - Vimarsana News

Licensing Agreement to Drive Multi-specific Biotherapeutics Development

Zhejiang Doer Biologics Co, Ltd and Lonza have entered into a research license agreement for Doer Biologics to use Lonza’s XS Technologies® offering for production of its proprietary MultipleBody® and SMART-VHHBody platform technology. Click to read more...

Lonza and Doer Biologics in expression system license deal - Vimarsana News

Lonza and Doer Biologics in expression system license deal

Lonza has signed a licensing agreement with clinical-stage biopharma, Zhejiang Doer Biologics, whereby the Hangzhou, China based biopharma company will develop multi-specific biotherapeutics using the Swiss CDMO’s XS Pichia.